Clinical importance of the cytochromes P450

Lancet

Volumn 360, Issue 9340, 2002, Pages 1155-1162

  Nebert, Daniel W ^a   Russell, David W ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BILE ACID; CHOLESTEROL; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 3A; ICOSANOID; RIFAMPICIN; STEROID HORMONE;

BIOSYNTHESIS; CHOLESTEROL METABOLISM; DETOXIFICATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SPECIFICITY; GENOMICS; HUMAN; HYDROXYLATION; MOLECULAR BIOLOGY; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEROIDOGENESIS;

EID: 0037068964     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11203-7     Document Type: Review

References (72)

1. 3-450. Gene. 29:1984;281-292.
2. Nebert D.W., Gonzalez F.J. P450 genes: structure, evolution and regulation. Annu Rev Biochem. 56:1987;945-993.
3. Nebert D.W., Adesnik M., Coon M.J., et al. The P450 gene superfamily: recommended nomenclature. DNA. 6:1987;1-11.
4. Nelson DR. Cytochrome P450 gene superfamily. Available at http://drnelson.utmem.edu/cytochromeP450.html (accessed July 10, 2002).
5. Gonzalez F.J., Nebert D.W. Evolution of the P450 gene superfamily: animal-plant "warfare," molecular drive, and human genetic differences in drug oxidation. Trends Genet. 6:1990;182-186.
6. Nelson D.R., Kamataki T., Waxman D.J., et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell Biol. 12:1993;1-51.
7. Nebert DW, Nelson DR. Cytochrome P450 (CYP) superfamily. In: Cooper DN, ed. Encyclopaedia of the Human Genome [online]. London: Nature Publishing Group (in press): article 667. http://www.naturereference.com/ehg/ehg.htm.
8. Nebert D.W., Dieter M.Z. The evolution of drug metabolism. Pharmacology. 61:2000;124-135.
9. Schuetz E.G. Induction of cytochromes P450. Curr Drug Metab. 2:2001;139-147.
10. Tang W., Stearns R.A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab. 2:2001;185-198.
11. Oscarson M, Ingelman-Sundberg M, Daly AK, Nebert DW. Human cytochrome P450 (CYP) alleles. Available at http://www.imm.ki.se/CYPalleles/ (accessed July 10, 2002).
12. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet. 356:2000;1667-1671.
13. Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2:2001;9-39.
14. Phillips K.A., Veenstra D.L., Oren E., Lee J.K., Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 286:2001;2270-2279.
15. Nebert D.W., Jorge-Nebert L.F. Pharmacogenetics and pharmacogenomics. Rimoin D.L., Connor J.M., Pyeritz R.E., Korf B.R., Emery and Rimoin's Principles and Practice of Medical Genetics. 4th edn. 2002;590-631 Harcourt Brace, Edinburgh.
16. Clapper M.L. Genetic polymorphism and cancer risk. Curr Oncol Rep. 2:2000;251-256.
17. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants: the role of the CYP family of enzymes. Mutat Res. 482:2001;11-19.
18. Nebert D.W. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet. 59:1999;247-258.
19. Nebert D.W., Roe A.L., Dieter M.Z., Solis W.A., Yang Y., Dalton T.P. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem Pharmacol. 59:2000;65-85.
20. Plastaras J.P., Guengerich F.P., Nebert D.W., Marnett L.J. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem. 275:2000;11784-11790.
21. Smith A.G., Clothier B., Carthew P., et al. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol. 173:2001;89-98.
22. Hartter S., Wang X., Weigmann H., et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 21:2001;167-174.
23. Murray G.I., Taylor M.C., McFadyen M.C., et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57:1997;3026-3031.
24. Dalton T.P., Dieter M.Z., Matlib R.S., et al. Targeted knockout in the Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun. 267:2000;184-189.
25. Liang H.C.L., Li H., McKinnon R.A., et al. Cyp1a2(-/-) null mutant mice develop normally, but show deficient drug metabolism. Proc Natl Acad Sci USA. 93:1996;1671-1676.
26. Gonzalez F.J., Kimura S. Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice. Mutat Res. 477:2001;79-87.
27. Stoilov I., Akarsu A.N., Sarfarazi M. Identification of three different truncating mutations in the cytochrome P450 1B1 (CYP1B1) gene as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet. 6:1997;641-647.
28. Stoilov I. Cytochromes P450: coupling development and environment. Trends Genet. 17:2001;629-632.
29. Andreola F., Fernandez-Salguero P.M., Chiantore M.V., Petkovich M.P., Gonzalez F.J., De Luca L.M. Aryl hydrocarbon receptor Ahr(-/-) knockout mice exhibit liver retinoid accumulation and reduced retinoic acid metabolism. Cancer Res. 57:1997;2835-2838.
30. Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 37:1997;269-296.
31. Guengerich F.P., Hosea N.A., Parikh A., et al. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Drug Metab Dispos. 26:1998;1175-1178.
32. Fisslthaler B., Popp R., Kiss L., et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 401:1999;493-497.
33. Waxman D.J., Lapenson D.P., Aoyama T., Gelboin H.V., Gonzalez F.J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 290:1991;160-166.
34. Araya Z., Wikvall K. 6α-Hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Biochim Biophys Acta. 1438:1999;47-54.
35. Goodwin B., Redinbo M.R., Kliewer S.A. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol. 42:2002;1-23.
36. Lu A.Y.H., Somogyi A., West S., Kuntzman R., Conney A.H. Pregnenolone-16α-carbonitrile: a new type of inducer of drug-metabolizing enzymes. Arch Biochem Biophys. 152:1972;457-462.
37. Barwick J.L., Quattrochi L.C., Mills A.S., Potenza C., Tukey R.H., Guzelian P.S. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol. 50:1996;10-16.
38. Xie W., Barwick J.L., Downes M., et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 406:2000;435-439.
39. Watkins R.E., Wisely G.B., Moore L.B., et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 292:2001;2329-2333.
40. Selye H. Hormones and resistance. J Pharm Sci. 60:1971;1-28.
41. Moore L.B., Goodwin B., Jones S.A., et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA. 97:2000;7500-7502.
42. Xie W., Barwick J.L., Simon C.M., et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 14:2000;3014-3023.
43. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science. 294:2001;1866-1870.
44. Simpson A.E. The cytochrome P450-4 (CYP4) family. Gen Pharmacol. 28:1997;351-359.
45. Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney: role of CYP4F2 and CYP4A11. J Biol Chem. 275:2000;4118-4126.
46. Nebert D.W. Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol. 47:1994;25-37.
47. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 294:2001;1871-1875.
48. Hennan J.K., Huang J., Barrett T.D., et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 104:2001;820-825.
49. Tuder R.M., Cool C.D., Yeager M., Taraseviciene-Stewart L., Bull T.M., Voelkel N.F. The patho-biology of pulmonary hypertension: the endothelium. Clin Chest Med. 22:2001;405-418.
50. Nelson D.R., Koymans L., Kamataki T., et al. Cytochrome P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics. 6:1996;1-42.
51. Yoshida Y., Aoyama Y., Noshiro M., Gotoh O. Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. Biochem Biophys Res Commun. 273:2000;799-804.
52. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 102:2000;731-744.
53. Eggertsen G., Olin M., Andersson U., et al. Molecular cloning and expression of rabbit sterol 12α-hydroxylase. J Biol Chem. 271:1996;32269-32275.
54. Andersson S., Davis D.L., Dahlback H., Jornvall H., Russell D.W. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 27-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem. 264:1989;8222-8229.
55. Lund E.G., Guileyardo J.M., Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA. 96:1999;7238-7243.
56. Bjorkhem I., Boberg K.M., Leitersdort F. Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. Scriver C.R., Beaudet A., Sly W.S., et al. The Metabolic and Molecular Bases of Inherited Disease. 2001;2981-2988 McGraw-Hill, New York.
57. Pullinger C.R., Eng C., Salen G., et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiencey has a hypercholesterolemic phenotype. J Clin Invest. 110:2002;109-117.
58. Setchell K.D., Schwarz M., O'Connell N.C., et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J Clin Invest. 102:1998;1690-1703.
59. Ryner L.C., Swain A. Sex in the '90s. Cell. 81:1995;483-493.
60. Miller W.L., Geller D.H., Auchus R.J. The molecular basis of isolated 17,20-lyase deficiency. Endocr Res. 24:1998;817-825.
61. Nebert D.W., McKinnon R.A. Cytochrome P450: evolution and functional diversity. Progr Liv Dis. 12:1994;63-67.
62. Simpson E.R. Genetic mutations resulting in loss of aromatase activity in humans and mice. J Soc Gynecol Invest. 7:2000;S18-S21.
63. White P.C. Congenital adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab. 15:2001;17-41.
64. Wikvall K. Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form. Intl J Mol Med. 7:2001;201-209.
65. Corchero J., Granvil C.P., Akiyama T.E., et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse. Mol Pharmacol. 60:2001;1260-1267.
66. Honda A., Salen G., Matsuzaki Y., et al. Side-chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27(-/-) mice but not in cerebrotendinous xanthomatosis. J Biol Chem. 276:2001;34579-34585.
67. 3 1α-hydroxylase gene causes vitamin D-dependent rickets type I. Mol Cell Endocrinol. 156:1999;7-12.
68. Norman A.W., Ishizuka S., Okamura W.H. Ligands for the vitamin D endocrine system: different shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand for the plasma vitamin D binding protein. J Steroid Biochem Mol Biol. 76:2001;49-59.
69. St-Arnaud R., Arabian A., Travers R., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1α,25-dihydroxy-vitamin D and not to the absence of 24,25-dihydroxy-vitamin D. Endocrinology. 141:2000;2658-2666.
70. Stoilov I., Jansson I., Sarfarazi M., Schenkman J.B. Roles of cytochrome P450 in development. Drug Metabol Drug Interact. 18:2001;33-55.
71. Nebert D.W. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics. 10:2000;279-290.
72. Kruglyak L., Nickerson D.A. Variation is the spice of life. Nat Genet. 27:2001;234-236.